SCHEMBL4910620

SCHEMBL4910620

C=C(c1ccc(I)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 20/20 0.72
RXRB P28702 7/20 0.72
RXRG P48443 7/20 0.72
RARB P10826 5/20 0.72
RARG P13631 4/20 0.72
RARA P10276 2/20 0.72
MEN1 O00255 1/20 0.72
CYP26A1 O43174 1/20 0.72
ABCB11 O95342 1/20 0.72
ESR1 P03372 1/20 0.72
PGR P06401 1/20 0.72
HTR1A P08908 1/20 0.72
ADRA2A P08913 1/20 0.72
ADORA3 P0DMS8 1/20 0.72
CHRM1 P11229 1/20 0.72
DRD1 P21728 1/20 0.72
TBXA2R P21731 1/20 0.72
SLC6A2 P23975 1/20 0.72
ADRA1A P35348 1/20 0.72
OPRM1 P35372 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7756699 0.86 RXRA (0.78) RXRARXRBRXRGRARBRARG
SCHEMBL7760712 0.86 RXRA (0.61) RXRARXRBRXRGRARBRARG
SCHEMBL13846924 0.85 RXRA (0.72) RXRARXRBRXRGRARBRARG
SCHEMBL4004146 0.85 RXRA (0.72) RXRARXRBRXRGRARBRARG
SCHEMBL12755164 0.84 RXRA (0.79) RXRARXRBRXRGRARBRARG
SCHEMBL12181009 0.84 RXRA (0.79) RXRARXRBRXRGRARBRARG
Bexarotene SCHEMBL9025 0.84 RXRA (1.00) RXRARXRBRXRGRARBRARG
Bexarotene SCHEMBL29412584 0.84 RXRA (1.00) RXRARXRBRXRGRARBRARG
Bexarotene SCHEMBL5322954 0.84 RXRA (1.00) RXRARXRBRXRGRARBRARG
SCHEMBL14068120 0.83 RXRA (0.50) RXRARXRBRXRGRARBRARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114361717-A Composite separator and electrochemical device 珠海冠宇电池股份有限公司 2022-04-15 CN claimed
US-20230125852-A1 SEPARATOR AND BATTERY INCLUDING SEPARATOR ZHUHAI COSMX BATTERY CO., LTD. (CN) 2023-04-27 US disclosed
EP-4156401-A1 DIAPHRAGM, AND BATTERY COMPRISING SAME Zhuhai CosMX Battery Co., Ltd. (CN) 2023-03-29 EP disclosed
CN-218498299-U Diaphragm, roll up core and battery 珠海冠宇电池股份有限公司 2023-02-17 CN disclosed
CN-115411456-A Diaphragm, roll up core and battery 珠海冠宇电池股份有限公司 2022-11-29 CN disclosed
CN-113363575-B Sulfonic polymer eutectic solid electrolyte and preparation method thereof 中国科学院青岛生物能源与过程研究所 2022-08-26 CN disclosed
CN-111613399-B PTC material and application thereof 珠海冠宇电池股份有限公司 2022-07-22 CN disclosed
CN-114641890-A Diaphragm and high-voltage battery comprising same 珠海冠宇电池股份有限公司 2022-06-17 CN disclosed
CN-114583412-A Negative pole piece and lithium ion battery comprising same 珠海冠宇电池股份有限公司 2022-06-03 CN disclosed
CN-112615107-B Microsphere, diaphragm containing microsphere and lithium ion battery containing diaphragm 珠海冠宇电池股份有限公司 2022-04-22 CN disclosed
CN-111048722-A Organic-inorganic composite lithium ion conduction diaphragm, preparation method thereof and lithium-oxygen battery obtained by using same 河南大学 2020-04-21 CN disclosed
CN-111029514-A Diaphragm and high-voltage battery comprising same 珠海冠宇电池有限公司 2020-04-17 CN disclosed
US-10546783-B2 Manufacturing process of element chip and substrate heating apparatus PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) 2020-01-28 US disclosed
US-20190006238-A1 MANUFACTURING PROCESS OF ELEMENT CHIP AND SUBSTRATE HEATING APPARATUS PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) 2019-01-03 US disclosed
US-20080297906-A1 Anisotropic Diffusion Film TORAY INDUSTRIES, INC. (JP) 2008-12-04 US disclosed
US-20080234229-A1 Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders AUSPEX PHARMACEUTICALS, INC. (US) 2008-09-25 US disclosed
US-20080234229-A1 Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders AUSPEX PHARMACEUTICALS, INC. (US) 2008-09-25 US disclosed
US-20080234229-A1 Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders AUSPEX PHARMACEUTICALS, INC. (US) 2008-09-25 US disclosed
EP-1767962-A1 ANISOTROPIC DIFFUSION FILM TORAY INDUSTRIES, INC. (JP) 2007-03-28 EP disclosed
WO-2007022437-A2 THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER AND METABOLIC DISORDERS AUSPEX PHARMACEUTICALS, INC. (US) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234229-A1 Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders IGF1R, INSR, BRCA1 RXRA 494/4885RXRB 487/4885RXRG 526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.